Tempus AI Inc
NASDAQ:TEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Addtech AB
STO:ADDT B
|
SE |
Tempus AI Inc
Depreciation & Amortization
Tempus AI Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tempus AI Inc
NASDAQ:TEM
|
Depreciation & Amortization
-$16.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Depreciation & Amortization
-$1.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Danaher Corp
NYSE:DHR
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Waters Corp
NYSE:WAT
|
Depreciation & Amortization
-$47.8m
|
CAGR 3-Years
-96%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-17%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Depreciation & Amortization
-$1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Tempus AI Inc
Glance View
Tempus AI Inc. stands at the forefront of the healthcare technology revolution, focusing its expertise on the convergence of artificial intelligence and big data to transform the way doctors approach precision medicine. Founded by Eric Lefkofsky in 2015, the company’s mission is to harness the power of data, equipping physicians with crucial insights that can propel patient care forward. With its sprawling genomic database, Tempus aggregates clinical and molecular information, which is then meticulously analyzed to provide actionable insights. Physicians receive comprehensive reports, offering tailored therapeutic options and clinical trial opportunities that might otherwise remain undiscovered. Monetization for Tempus hinges on its relationships with various stakeholders in the healthcare ecosystem. It primarily earns revenue through partnerships with pharmaceutical companies, where it assists in drug discovery and development by offering detailed genomic data and analytics. Moreover, Tempus collaborates with research institutes and healthcare providers who rely on its AI-driven platform to enhance clinical decision-making and improve treatment outcomes. By bridging the gap between vast datasets and intricate patient care solutions, Tempus not only facilitates better healthcare practices but also solidifies its role as a vital link in the evolving landscape of modern medicine.
See Also
What is Tempus AI Inc's Depreciation & Amortization?
Depreciation & Amortization
-16.3m
USD
Based on the financial report for Dec 31, 2025, Tempus AI Inc's Depreciation & Amortization amounts to -16.3m USD.
What is Tempus AI Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-23%
Over the last year, the Depreciation & Amortization growth was -33%. The average annual Depreciation & Amortization growth rates for Tempus AI Inc have been -24% over the past three years , -23% over the past five years .